Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of NAT, GST, and CYP2E1 Genetic Variation in Sub-Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases.

Clinical pharmacology and therapeutics - 1 May 2025

Malinga Thandeka V B, Othman Houcemeddine, Paximadis Maria, Tiemessen Caroline T, Ramsay Michèle, Hazelhurst Scott, Twesigomwe David

Abstract excerpt

Tuberculosis (TB) is a major health burden in Africa. Although TB is treatable, anti-TB drugs are associated with adverse drug reactions (ADRs), which are partly attributed to pharmacogenetic variation. The distribution of star alleles (haplotypes) influencing anti-TB drug metabolism is unknown in many African populations. This presents challenges in implementing genotype-guided therapy in Africa to decrease the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Africa South of the Sahara
Share to Antitubercular Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arylamine N-Acetyltransferase

Share to Cytochrome P-450 CYP2E1

Share to Glutathione Transferase

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Share to Tuberculosis

Source

Open in PubMed Open full text

Identifiers

PMID: 39829327
DOI: 10.1002/cpt.3557
PMCID: PMC11993289

Genes

NAT1
NAT2
CYP2E1
GSTM1
GSTT1
GSTP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of NAT, GST, and CYP2E1 Genetic Variation in Sub-Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases.PMID 39829327Read ↗

In-silico functional prediction of novel tuberculosis pharmacogenetic variants and NAT2 phenotype prediction in African populationsSemantic proximity Read ↗

Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub-Saharan African Populations.Semantic proximity Read ↗

Characterization of CYP2D6 Pharmacogenetic Variation in Sub-Saharan African Populations.Semantic proximity Read ↗

Towards pharmacogenomics-guided tuberculosis (TB) therapy: N-acetyltransferase-2 genotypes among TB-infected Kenyans of mixed ethnicity.Semantic proximity Read ↗

Pharmacogenetic Study of Drugs Affecting Mycobacterium tuberculosis.Semantic proximity Read ↗

Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.Semantic proximity Read ↗

Mapping the Pharmacogenetic Landscape in a Ugandan Population: Implications for Personalized Medicine in an Underrepresented Population.Semantic proximity Read ↗

Genetic Landscape of NAT2 in the Moroccan Population: Implications for Isoniazid Pharmacogenetics in Tuberculosis.Semantic proximity Read ↗

Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil.Semantic proximity Read ↗

Characterization of POR haplotype distribution in African populations and comparison with other global populations.Semantic proximity Read ↗

Genetic polymorphisms and adverse reactions to antituberculosis therapySemantic proximity Read ↗

Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.